New Cancer Drug Approved to Help British Patients

Health officials in Britain have approved a new drug called Elahere to treat ovarian cancer. The drug is made by a company called AbbVie and will help patients whose cancer doesn't get better with regular treatments. About 270 patients will be able to use this medicine in the first year. The drug will be paid for by Britain's National Health Service, which provides free healthcare to all citizens.

Elahere is a special type of medicine that doctors call a 'guided missile' cancer therapy. This means it can find and attack cancer cells while leaving healthy cells alone. The drug is given to patients once every three weeks through an injection. It causes fewer side effects than chemotherapy, which is the usual treatment for cancer.

Before this approval, patients could only get Elahere through special research studies or by paying for private care. Now, all patients who need it can get the drug for free through the NHS. The health officials made this decision after changing their rules about which medicines they will pay for. The new rules make it easier for patients to get expensive treatments.

In tests with 453 patients, Elahere helped people live longer than regular chemotherapy. Patients who took Elahere lived an average of 16.9 months, while those on chemotherapy lived 13.3 months. The new drug also delayed the cancer from getting worse for 5.6 months compared to 4 months with chemotherapy. These results show that the new medicine works better than older treatments.

Victoria Clare, who runs a charity that helps people with ovarian cancer, said this is very important news. She explained that this is the first new treatment option for ovarian cancer patients in more than 20 years. The approval gives hope to women who have run out of other treatment choices. Many families will be grateful for this new option.